# Efficacy and Safety of Asenapine With Placebo and Olanzapine (41021)(P05933)

> **NCT00156117** · PHASE3 · COMPLETED · sponsor: **Organon and Co** · enrollment: 417 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** asenapine
- **DRUG:** Placebo
- **DRUG:** olanzapine

## Key facts

- **NCT ID:** NCT00156117
- **Lead sponsor:** Organon and Co
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-05-12
- **Primary completion:** 2006-04-28
- **Final completion:** 2006-05-30
- **Target enrollment:** 417 (ACTUAL)
- **Last updated:** 2024-08-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00156117

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00156117, "Efficacy and Safety of Asenapine With Placebo and Olanzapine (41021)(P05933)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00156117. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*